Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Ranibizumab (Lucentis) Therapy in Patients with Diabetic Ischaemic Macular Oedema (DIME)
2013-000031-27Phase 3Terminated
- Sponsor
- Moorfields Eye Hospital
- Start
- Feb 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Moorfields Eye Hospital. Primary endpoint: Safety of intravitreal ranibizumab in DIME. Started Feb 2013; status: terminated.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2013-000031-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000031-27.